Research programme: stroke therapy - Vernalis
Latest Information Update: 20 Jun 2002
At a glance
- Originator Vernalis Group
- Mechanism of Action GABA receptor agonists; Glutamate receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 20 Jun 2002 Discontinued - Preclinical for Stroke in United Kingdom (unspecified route)
- 15 Jun 2000 Preclinical development for Stroke in United Kingdom (Unknown route)